Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Back To The Future: Gilead Signs Up Four Indian Companies To License Late-stage AIDS Therapies

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In a strategic step looking to protect intellectual property rights while ensuring access to affordable life-saving medicines in developing nations, anti-HIV drugs specialist Gilead Sciences Inc. struck licensing deals July 12 with four India-based drug manufacturers - Hetero Drugs Ltd., Ranbaxy Laboratories Ltd., Strides Arcolab Ltd., and Matrix Laboratories Ltd. - for three Gilead drugs that are in late-stage clinical development

You may also be interested in...



Relevant Pipeline Brings Gilead Closer to Direct Indian Presence

Long after it has established business links with Indian drug makers, Gilead Sciences is looking to set up its own India office. All these years, the US firm has stopped shy of a direct presence but the growing relevance of its drug pipeline to the local population now makes this a strategic imperative, say industry insiders.

Gilead May Face Uphill Task With Sovaldi Despite Voluntary License Plan With Indian Generic Firms

Gilead may face unexpected speed bumps related to Sovaldi patents in India as it tries to extend the reach of its breakthrough HCV treatment via a combination of strategies, including voluntary licenses with Indian generics firms.

Asia Spotlight: Gilead Won’t Give Up Easily On Viread Patent Battle In China

China’s State Intellectual Property Office announced the invalidation of a patent for Viread, which is manufactured by Gilead and distributed by GSK in China. However, Gilead still holds several patents to protect the drug in China.

Related Content

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel